Marinomed focuses on growth after successful restructuring

• Marinomed plans to achieve an operating profit in 2025
• Budesolv: innovation for the treatment of allergic rhinitis
• Switzerland as a stepping stone for global expansion

Korneuburg, Austria, 27. March 2025 – Marinomed Biotech AG (VSE:MARI) has realigned its finances after a successful restructuring and is optimistic about the future. After receiving a first payment of EUR 5 million, further financial stability should be ensured by the milestone payments and the ongoing transition service agreement following the sale of the Carragelose business to Unither Pharmaceuticals. This allows Marinomed to focus operationally on the Marinosolv technology, which is used to enhance the solubility of hydrophobic compounds. This increases their bioavailability and enables a faster onset of action.

The current focus is on Budesolv, an innovative nasal corticosteroid for the treatment of severe allergic rhinitis (hay fever). Thanks to the Marinosolv technology, the required dose of commercially available active pharmaceutical ingredients can be reduced by around 85%, while Budesolv takes effect after just a few hours – in contrast to current active pharmaceutical ingredients, which take several days to reach full effect. In addition, Budesolv does not contain any harmful preservatives. The global market for allergic rhinitis has a volume of around USD 13 billion.

The management has a clear strategy for marketing. In order to accelerate negotiations with potential pharmaceutical partners around the world, Budesolv shall be initially approved in a smaller market. Switzerland shall be the first step because the discussions and negotiations with potential partners and the Swiss regulatory authority Swissmedic are most advanced there. At the same time, the corresponding manufacturing capacity will be established to obtain approval in Switzerland as quickly as possible together with a potential partner. At the same time, discussions are being held regarding marketing in larger markets. In the medium term, the management aims to achieve a significant market share in the global rhinitis segment.

A solid financial basis is the foundation for the next operational successes. Following the completion of the restructuring process and the sale of the Carragelose business, Marinomed is on the right track. According to preliminary calculations, the 2024 financial statements will close with a significant loss of around EUR 15 million due to the insolvency. After the legal completion of the restructuring proceedings, Marinomed will report a profit of around EUR 18.9 million in the first quarter of 2025 as a result of the restructuring alone. In addition, a first partial payment of EUR 5 million from the sale of the Carragelose business has already been received, so that the Company currently has sufficient liquid funds.

“By focussing on our business, the successful restructuring and the associated reduction in expenses, we plan to achieve positive operating results from this year onwards. The aim now is to regain the confidence of our shareholders through operational success,” explains Andreas Grassauer, founder and CEO of Marinomed Biotech AG.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.

For further inquiries contact:

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.